PYXIS ONCOLOGY INC
PYXSNASDAQ🏆 #2720 by market capEarnings Aug 12 · PostUS Equity
$686.21▲ $54.55 (+7.95%)
Simulated price1h—
24h▲ 8.0%
7d—
14d—
30d—
1y—
🏦Market Cap
$243M
Small Cap
📈Revenue Growth (YoY)
-14.2%
Declining
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
65
Fair
No chart data available for PYXS.
Trading Snapshot
- Day Range
- $682.44 – $690.97
- 52-Week Range
- $0.97 – $5.55
- Volume
- $2.54B
- Avg Volume
- $2.02B
- Shares Outstanding
- 83.0M
- Next Earnings
- Oct 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $23M
- Last Q Revenue
- $6M
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-0.93
- Dividend Yield
- —
Why Investors Own PYXS
- ✓High-growth profile — revenue up +16.6% YoY with expanding US Equity exposure.
- ✓Healthy economics — 76% gross margin and 23% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$23M▲ +11.4% YoY
Gross Margin (TTM)
75.8%▲ +3.8% YoY
Operating Income (TTM)
$8M▲ +11.4% YoY
Free Cash Flow (TTM)
$5M▲ +11.4% YoY
About PYXIS ONCOLOGY INC
A company profile for PYXIS ONCOLOGY INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Fair
65/100
Analyst Price Target
ⓘAverage Target
$726.35
▲ +5.8% Upside
High Target$823.74
Low Target$556.67
Based on 23 analysts
Latest News & Updates
🚀
MarketWatch·2h ago
PYXIS ONCOLOGY INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
Bloomberg·5h ago
Analysts lift PYXS price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
PYXIS ONCOLOGY INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.